期刊文献+

上海地区输血后丙型肝炎病毒感染者临床流行病学分析

The clinical epidemiologic characteristics of patients infected with hepatitis C virus post blood transfusion in Shanghai area
原文传递
导出
摘要 目的分析上海地区输血后HCV感染者的临床流行病学特点。方法采用PCR检测HCVRNA载量、ELISA检测抗-HCV,分析输血后HCV感染者的年龄、原发病因、暴露年份、输血成分与输血量、潜伏期和肝功能损害等。计数资料采用X^2检验,计量资料采用t检验和相关分析。结果327例中的279例(85.3%)感染者HCVRNA载量≥3.0log10拷贝/mL、中位数为5.99log10拷贝/mL;19.7%病例为3.0~4.0log10拷贝/mL,69.9%为5.0~6.0log10拷贝/mL。HCVRNA定性阳性率为81.6%(40/49),抗-HCV阳性率达99.7%(383/384),其阳性敏感度高于HCVRNA定量和定性检测(F=57.138,P=0.000;F=63.149,P=0.000)。输血后HCV+感染以30~60岁年龄段多见,84.4%病例暴露时间为1990年至1994年间,感染者中10%以上总病例数的疾病分别为妇产科、骨科疾病和胃肠道出血。输入全血者占80.0%,输血至临床诊断时间平均为(86.0±54.6)个月。89.0%感染者有肝功能损伤,但大多数ALT升高水平≤5×正常值上限(ULN)。结论输血后HCV感染以成年人居多,常伴有肝功能损伤,但ALT升高≤5×ULN;血清HCVRNA载量多为中等水平。 Objective To investigate the clinical epidemiologic characteristics of patients with hepatitis C virus (HCV) infection post blood transfusion. Methods The polymerase chain reaction (PCR) and enzyme linked immunosorbent assay (ELISA) were used to detect HCV RNA and anti- HCV, respectively. Analysis was performed for patients' age distribution, cause of primary diseases, exposure years, ingredient and amount of transfusion, incubation period and liver function damage. The statistical processing were performed with chi-square test, t-test and correlation analysis. Results HCV RNA levels were higher than 3.0 log10 copy/mL in 85.3% infected patients with a median of 5.99 log10 copy/mL, among Which 19.7% patients showed viral load 3.0 to 4.0 log10 copy/mL and 69.9% showed 5.0 to 6.0 log10 copy/mL. Eighty-one point six percent (40/49) of infected persons were confirmed as HCV RNA positive by HCV RNA qualitative analysis, while 99. 7% (383/384) patients were detected as anti-HCV positive by serological test. The sensitivity of serological test was higher than both HCV RNA quantitative and qualitative assays (F=57. 138, P=0.000; F=63. 149, P= 0. 000, respectively). HCV infection post blood transfusion was more common in people of 30 to 60 years old. Most cases (84.4%) got the first time exposure during 1990 to 1994. More than 10% cases had primary disease as obstetrics, orthopedics or gastrointestinal tract hemorrhage. Eighty percent received whole blood product transfusion. The mean interval between transfusion and clinical diagnosis was (86.0 ± 54.6) months. Eighty-nine percent of infected patients had liver function damage, while most of them showed elevated alanine aminotransferase (ALT) with no more than 5 upper limits of normal (ULN). Conclusions Post transfusion HCV infection mainly happened in adulthood. Infected patients usually have liver'function damage with elevated ALT with no more than 5 ULN and medium HCV RNA levels.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2008年第5期298-301,共4页 Chinese Journal of Infectious Diseases
关键词 肝炎 丙型 输血传播病毒 流行病学 上海 Hepatitis C, Transfusion-transmitted virus Epidemiology Shanghai
  • 相关文献

参考文献7

  • 1National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology, 1997,26(3 Suppl 1):2S-10S.
  • 2Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med, 1997,336: 347-356.
  • 3丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 4Lau G, Zhuang H. Top hepatology issues in China. J Gastoenterol Hepatol,2002, 17 (Suppl):A9.
  • 5Alter MJ. Epidemiology of viral hepatitis and HIV eoinfeetion. J Hepatol, 2006,44 (1 Suppl):S6-S9.
  • 6Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep, 1998,47: 1-39.
  • 7Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep, 2003,52 (RR 3):1-13,15.

二级参考文献15

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献734

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部